These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18250117)

  • 21. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.
    Koseoglu ST; Harmatz P; Turbeville S; Nicely H
    Int Ophthalmol; 2009 Aug; 29(4):267-9. PubMed ID: 18418554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review.
    Gomes DF; Gallo LG; Leite BF; Silva RB; da Silva EN
    J Inherit Metab Dis; 2019 Jan; 42(1):66-76. PubMed ID: 30740728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
    Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
    J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
    Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
    Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme].
    Bégin P; Chapdelaine H; Lemyre E; Paradis L; Des Roches A
    Ann Allergy Asthma Immunol; 2013 Jan; 110(1):55-6. PubMed ID: 23244660
    [No Abstract]   [Full Text] [Related]  

  • 26. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
    Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
    Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively.
    Bagewadi S; Roberts J; Mercer J; Jones S; Stephenson J; Wraith JE
    J Inherit Metab Dis; 2008 Dec; 31(6):733-7. PubMed ID: 18923918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
    Brands MM; Hoogeveen-Westerveld M; Kroos MA; Nobel W; Ruijter GJ; Özkan L; Plug I; Grinberg D; Vilageliu L; Halley DJ; van der Ploeg AT; Reuser AJ
    Orphanet J Rare Dis; 2013 Apr; 8():51. PubMed ID: 23557332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
    Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
    Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
    Politei J; Schenone A; Blanco M; Szlago M
    Arch Argent Pediatr; 2014 Jun; 112(3):258-62. PubMed ID: 24862809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.
    Sohn YB; Park SW; Kim SH; Cho SY; Ji ST; Kwon EK; Han SJ; Oh SJ; Park YJ; Ko AR; Paik KH; Lee J; Lee DH; Jin DK
    Am J Med Genet A; 2012 May; 158A(5):1158-63. PubMed ID: 22495825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong.
    But WM; Wong MY; Chow JC; Chan WK; Ko WT; Wu SP; Wong ML; Miu TY; Tse WY; Hung WW; Fan TW; Shek CC
    Hong Kong Med J; 2011 Aug; 17(4):317-24. PubMed ID: 21813902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
    Whitley CB; Utz JR
    Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?
    Pitz S; Ogun O; Arash L; Miebach E; Beck M
    Graefes Arch Clin Exp Ophthalmol; 2009 Jul; 247(7):975-80. PubMed ID: 19159944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Giugliani R; D Schwartz IV; Guffon N; Teles EL; Miranda MCS; Wraith JE; Beck M; Arash L; Scarpa M; Ketteridge D; Hopwood JJ; Plecko B; Steiner R; Whitley CB; Kaplan P; Yu ZF; Swiedler SJ; Decker C;
    Mol Genet Metab; 2008 Aug; 94(4):469-475. PubMed ID: 18502162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings.
    Leal GN; de Paula AC; Morhy SS; Andrade JL; Kim CA
    Cardiol Young; 2014 Apr; 24(2):229-35. PubMed ID: 23458163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI.
    Mühlstein A; Gelperina S; Kreuter J
    Pharmazie; 2013 Jul; 68(7):549-54. PubMed ID: 23923636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.